AIDS 2026 | Tembeka Sineke: A Randomized Trial Exploring Integration of U=U Interventions into Standardized HIV Care for Adolescents in South Africa

AIDS 2026 | Tembeka Sineke: A Randomized Trial Exploring Integration of U=U Interventions into Standardized HIV Care for Adolescents in South Africa

The 2026 International AIDS Conference (AIDS 2026) was held in Rio de Janeiro, Brazil. HIV care for adolescents and the rollout of the Undetectable = Untransmittable (U=U) framework emerged as key discussion priorities at the conference. Young populations across sub-Saharan Africa bear a dual burden of HIV infection and pervasive social stigma. Integrating U=U interventions into routine clinical care serves as a critical pathway to improve their disease literacy, psychological wellbeing, and reduce high-risk sexual behaviours.
AIDS 2026 | Dr. Santos: Distinguishing Muscle Quantity from Muscle Quality to Refine Sarcopenia Assessment Systems in Older Adults Living with HIV

AIDS 2026 | Dr. Santos: Distinguishing Muscle Quantity from Muscle Quality to Refine Sarcopenia Assessment Systems in Older Adults Living with HIV

The 2026 International AIDS Conference (AIDS 2026) was held in Rio de Janeiro, Brazil, where the management of sarcopenia among older adults living with HIV emerged as a hot topic of discussion. Dr. Andre dos Santos from the National Council for Scientific and Technological Development, Brazil, conducted a special study on the correlations between muscle quantity, muscle quality, muscle strength and physical performance in older HIV-positive patients using multimodal imaging techniques. His research findings have drawn widespread attention from clinical peers. Older adults living with HIV suffer prominent skeletal muscle damage due to chronic inflammation and long-term antiretroviral therapy (ART). Traditional assessment models that rely solely on muscle quantity have clear limitations. Infectious Disease Frontier conducted an exclusive interview with Dr. Santos to conduct in-depth discussions on core clinical issues including optimized sarcopenia assessment frameworks and stratified intervention strategies, offering new insights for long-term health management of older adults living with HIV.
AIDS 2026 | Dr. Vizcaino: Focus on Harms of Late HIV Diagnosis in Cuba and Explore Efficient Early Diagnosis, Prevention and Control Strategies

AIDS 2026 | Dr. Vizcaino: Focus on Harms of Late HIV Diagnosis in Cuba and Explore Efficient Early Diagnosis, Prevention and Control Strategies

The 2026 International AIDS Conference was held in Rio de Janeiro, Brazil, where scholars from across the globe engaged in in-depth exchanges on the latest advances in HIV diagnosis, treatment, prevention and control. Dr. Milena Duque Vizcaino from the Pedro Kourí Tropical Medicine Institute in Cuba presented a domestic follow-up study covering 2019 to 2025 at the conference, centering on the critical public health issue linking late HIV diagnosis to mortality risk. Though Cuba has built a comprehensive HIV prevention and control network underpinned by its unique universal free healthcare system, the challenge of delayed diagnosis has not been fully eliminated. Infectious Disease Frontier conducted an exclusive interview with Dr. Vizcaino to discuss core topics including disparities in mortality risk among late-diagnosed patients, key barriers to delayed diagnosis, and optimized screening and intervention pathways. The interview analyzes pain points and practical experience of HIV prevention under a Latin American medical model, offering reference frameworks for low- and middle-income regions worldwide to refine strategies for early HIV screening and treatment.
AIDS 2026 | Professor McMahon: Exploring the Clinical Potential of Half-Yearly Long-Acting Triple Regimens for HIV Treatment

AIDS 2026 | Professor McMahon: Exploring the Clinical Potential of Half-Yearly Long-Acting Triple Regimens for HIV Treatment

The 2026 International AIDS Conference (AIDS 2026) was successfully held in Rio de Janeiro, Brazil. The conference covered multi-dimensional topics including HIV prevention, diagnosis and treatment, and long-term disease management, bringing together scholars from the global infectious disease field for academic exchanges. Professor James McMahon from the Alfred Hospital and Monash University, Australia presented data from a 104-week Phase II clinical trial at the conference, focusing on evaluating the efficacy and safety of a half-yearly long-acting triple regimen combining lenacapavir, teropavimab and zinlirvimab. Long-acting administration represents a key developmental direction for current HIV therapy, drastically alleviating the daily pill-taking burden on patients and offering new insights for optimized long-term disease management. Infectious Disease Frontier conducted an exclusive interview with Professor McMahon to discuss the sustained viral suppression effects, tolerability profiles and target patient populations of this innovative long-acting triple regimen based on core primary clinical trial data, for reference by frontline clinical practitioners.
Professor Xuewen Jiang: Deepening MDT Collaboration to Advance Standardized Diagnosis and Treatment in Urologic Oncology

Professor Xuewen Jiang: Deepening MDT Collaboration to Advance Standardized Diagnosis and Treatment in Urologic Oncology

As diagnostic concepts and treatment strategies for urologic malignancies continue to evolve, clinical decision-making is shifting from relatively specialized, single-discipline treatment toward multidisciplinary, comprehensive management throughout the disease course. Multidisciplinary team (MDT) care integrates expertise from surgery, medical oncology, radiation oncology, radiology, pathology, and other specialties to develop more standardized, precise, and individualized treatment strategies for patients with complex and challenging disease. It has therefore become an important pathway for improving the quality of urologic oncology care. Oncology Frontier · UroStream invited Professor Xuewen Jiang of Qilu Hospital of Shandong University for an exclusive interview to share his experience with MDT practice in urologic oncology and discuss future directions for optimizing and expanding the model.
Professor Yanbo Wang: Strengthening End-to-End Quality Control and Data Governance to Build a High-Quality Clinical Research System in Urology

Professor Yanbo Wang: Strengthening End-to-End Quality Control and Data Governance to Build a High-Quality Clinical Research System in Urology

High-quality clinical research is an essential foundation for advancing medicine and improving patient outcomes. In urology, establishing robust top-level research design and end-to-end quality control, transforming large volumes of clinical records into standardized and usable research data, and helping young physicians identify research opportunities amid demanding clinical workloads have become important priorities in disciplinary development. In this issue of Oncology Frontier · UroStream, Professor Yanbo Wang of the First Hospital of Jilin University discusses the full-process quality control of clinical research in urology, clinical database development and data governance, as well as pathways for young physicians to develop their research careers, sharing practical experience and insights into building a high-quality clinical research system.
Professor Shouzhen Chen: Combining PI-RADS and PHI Density for Precise Risk Stratification and Optimizing Repeat Prostate Biopsy Decisions

Professor Shouzhen Chen: Combining PI-RADS and PHI Density for Precise Risk Stratification and Optimizing Repeat Prostate Biopsy Decisions

For patients with an initial negative prostate biopsy, whether and when to perform a repeat biopsy remains an important clinical challenge in the early diagnosis of prostate cancer. On the one hand, unnecessary repeat biopsies may increase patients' pain, bleeding, infection, and psychological burden; on the other hand, inadequate risk assessment may delay the diagnosis of clinically significant prostate cancer. How to use more precise risk-stratification tools to reduce unnecessary invasive procedures while maintaining a low risk of missing clinically significant cancer has therefore become an important area of clinical interest. In this issue of Oncology Frontier · UroStream, Professor Shouzhen Chen of Qilu Hospital of Shandong University discusses a risk-stratification and prediction model combining the Prostate Imaging Reporting and Data System (PI-RADS) score with the Prostate Health Index (PHI) and PHI density (PHID). He provides an in-depth interpretation of the model's key findings, clinical value, and current limitations in patients undergoing repeat biopsy, while also discussing future directions involving multimodal biomarkers and emerging molecular imaging technologies.
Professor Xin Yao: Precision Medicine and Minimally Invasive Technologies Working Together to Advance Urologic Oncology Care

Professor Xin Yao: Precision Medicine and Minimally Invasive Technologies Working Together to Advance Urologic Oncology Care

With the rapid development of molecular imaging, artificial intelligence, multi-omics technologies, and robotic surgery, the management of urologic cancers is gradually evolving from relatively standardized treatment toward more precise, minimally invasive, and individualized whole-course care. Precision medicine can improve the accuracy of tumor identification, risk stratification, and treatment selection, while robotic-assisted surgery provides important technical support for meticulous dissection, organ preservation, and functional reconstruction. Oncology Frontier · UroStream invited Professor Xin Yao of Tianjin Medical University Cancer Institute and Hospital for an exclusive interview to discuss pathways toward precision diagnosis and treatment in urologic oncology, as well as the clinical value and future directions of robotic surgery.
Advancing Clinical Innovation and Shaping the Future of Urology — Professor Liqun Zhou on the Development of Clinical Research and the Training of Young Urologists

Advancing Clinical Innovation and Shaping the Future of Urology — Professor Liqun Zhou on the Development of Clinical Research and the Training of Young Urologists

The Third Yellow River Urology Congress and the 31st Academic Conference of the Shandong Medical Association on Urology were recently held successfully. The conference brought together numerous experts and scholars in urology from across China to discuss cutting-edge advances, innovations in clinical practice, talent development, and regional collaboration. Oncology Frontier · UroStream invited Professor Liqun Zhou of Peking University First Hospital to provide an in-depth analysis of how to advance high-quality clinical research in urology and support the professional development of young physicians.
 Professor Shaoxing Zhu: Achieving Deep Testosterone Suppression and Maximizing Patient Benefit — Individualized ADT-Based Treatment Strategies for Prostate Cancer

 Professor Shaoxing Zhu: Achieving Deep Testosterone Suppression and Maximizing Patient Benefit — Individualized ADT-Based Treatment Strategies for Prostate Cancer

In recent years, the incidence and mortality of prostate cancer in China have increased significantly, driven by socioeconomic development and population aging, resulting in a growing disease burden. Androgen deprivation therapy (ADT), whether used alone or in combination, remains a cornerstone of comprehensive prostate cancer management. With updates to the Chinese Expert Consensus on Testosterone Management in Prostate Cancer and the Expert Consensus on Comprehensive Management of Prostate Cancer, clinical recommendations have evolved beyond achieving castration-level testosterone (<50 ng/dL) toward deep testosterone suppression (<20 ng/dL) and rapid, sustained PSA control, which may provide patients with better outcomes. Against this background, Oncology Frontier invited Professor Shaoxing Zhu of Fujian Medical University Union Hospital to discuss the evidence supporting deep testosterone suppression, individualized perioperative treatment strategies, and approaches that balance treatment efficacy with quality of life, with the goal of further improving survival and quality of life among patients with prostate cancer in China.